DK1045849T3 - Purinderivater, der har phosphodiesterase IV inhiberingsaktivitet - Google Patents

Purinderivater, der har phosphodiesterase IV inhiberingsaktivitet

Info

Publication number
DK1045849T3
DK1045849T3 DK98963053T DK98963053T DK1045849T3 DK 1045849 T3 DK1045849 T3 DK 1045849T3 DK 98963053 T DK98963053 T DK 98963053T DK 98963053 T DK98963053 T DK 98963053T DK 1045849 T3 DK1045849 T3 DK 1045849T3
Authority
DK
Denmark
Prior art keywords
compound
formula
group
reacting
effective amount
Prior art date
Application number
DK98963053T
Other languages
English (en)
Inventor
David Cavalla
Mark Chasin
Peter Hofer
Andre Gehrig
Peter Wintergerst
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK1045849T3 publication Critical patent/DK1045849T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK98963053T 1997-12-12 1998-12-11 Purinderivater, der har phosphodiesterase IV inhiberingsaktivitet DK1045849T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6937197P 1997-12-12 1997-12-12
PCT/US1998/026293 WO1999031102A1 (en) 1997-12-12 1998-12-11 Purine derivatives having phosphodiesterase iv inhibition activity

Publications (1)

Publication Number Publication Date
DK1045849T3 true DK1045849T3 (da) 2003-10-27

Family

ID=22088545

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98963053T DK1045849T3 (da) 1997-12-12 1998-12-11 Purinderivater, der har phosphodiesterase IV inhiberingsaktivitet

Country Status (19)

Country Link
US (5) US6040447A (da)
EP (3) EP1044201A4 (da)
JP (5) JP2002508378A (da)
KR (3) KR100349385B1 (da)
CN (3) CN1294590A (da)
AT (1) ATE244243T1 (da)
AU (5) AU1722899A (da)
BR (3) BR9815170A (da)
CA (3) CA2313004A1 (da)
DE (3) DE19882892T1 (da)
DK (1) DK1045849T3 (da)
ES (1) ES2202924T3 (da)
GB (2) GB2346879B (da)
HU (3) HUP0301166A2 (da)
NO (1) NO20002998L (da)
PL (1) PL341108A1 (da)
PT (1) PT1045849E (da)
TR (1) TR200001706T2 (da)
WO (5) WO1999031104A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367143A1 (en) * 1999-04-02 2000-10-12 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
EP1202628B1 (en) * 1999-08-12 2004-10-13 Euro-Celtique S.A. Novel hypoxanthine and thiohypoxanthine compounds
CN100439370C (zh) * 2001-02-08 2008-12-03 记忆药物公司 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2003261418B2 (en) * 2002-08-08 2010-05-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20040063938A1 (en) * 2002-09-30 2004-04-01 Pfizer Inc Process for preparing haloalkyl pyrimidines
BRPI0412502A (pt) * 2003-07-10 2006-09-19 Achillion Pharmaceuticals Inc derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
US20080280926A1 (en) * 2003-12-16 2008-11-13 Palle Venkata P Phosphodiesterase Inhibitors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
DE102006033572A1 (de) 2006-07-20 2008-01-24 Bayer Cropscience Ag N'-Cyano-N-halogenalkyl-imidamid Derivate
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101952455A (zh) 2007-12-17 2011-01-19 卢克斯创新有限公司 用于维护流体输导和容纳系统的组合物和方法
CN102405047B (zh) * 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102142A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (en) 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
ES2860648T5 (es) 2014-02-07 2024-11-27 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2017123766A1 (en) * 2016-01-12 2017-07-20 Sperovie Biosciences, Inc. Compounds and compositions for the treatment of disease
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
RU2746012C2 (ru) * 2019-05-13 2021-04-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956998A (en) 1960-10-18 Adenine derivatives and process
US2844577A (en) 1958-07-22 Certificate of correction
US2903455A (en) 1959-09-08 Jdnviiiiaisnvhi jo
US3215696A (en) * 1965-11-02 Substituted adenines -and preparation thereof
US2697709A (en) 1951-06-14 1954-12-21 Burroughs Wellcome Co Mercapto heterocycles and method of making
US2691654A (en) 1952-06-11 1954-10-12 Buroughs Wellcome & Co U S A I Amino heterocycles and method of making
US2966488A (en) 1956-07-30 1960-12-27 Shive William Substituted alkylaminopurines
US2957875A (en) 1957-11-18 1960-10-25 Upjohn Co Derivatives of purine
US3079378A (en) 1960-02-01 1963-02-26 Upjohn Co Acylated psicofuranosyladenines
BE601946A (da) 1960-03-31
US3135753A (en) 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
FR1548252A (da) 1961-10-13 1968-12-06
IL24679A (en) 1965-11-24 1971-10-20 Yissum Res Dev Co Derivatives of 3-methyl purine and methods of preparing the same
US3669979A (en) 1967-12-14 1972-06-13 Gaf Corp Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst
US3952001A (en) 1970-07-01 1976-04-20 The Boots Company Limited 1-Carbamoyl-1,2,4-triazoles
JPS5121529A (ja) 1974-08-16 1976-02-20 Hitachi Ltd Pirorinsandometsukizeiseihimakuboshiho
USRE31429E (en) 1977-02-14 1983-10-25 Merck & Co., Inc. Process for preparation of 9-(dihalobenzyl)adenines
GB2041359B (en) * 1979-01-10 1982-12-15 Ici Ltd Purine derivatives and their use in the defoliation of cotton plants
US4241063A (en) 1979-08-06 1980-12-23 Bristol-Myers Company Purine derivatives and their use as bronchodilators
US4361699A (en) 1981-09-28 1982-11-30 Merck & Co., Inc. Novel process for the preparation of N6 -alkyl-arprinocid
US4407802A (en) 1981-09-28 1983-10-04 Merck & Co., Inc. 6-Amidino-9-substituted benzyl purines
GB2120065B (en) 1982-04-27 1986-01-02 Michael Frederick Huber Heating plants
US4492592A (en) 1983-06-06 1985-01-08 Shell Oil Company Combined desiccation of substantially supercritical CO2
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US4883801A (en) 1984-09-07 1989-11-28 The General Hospital Corporation Xanthine derivative pest control agents
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
FI875724A0 (fi) 1986-04-29 1987-12-28 Pfizer Av kalcium oberoende camp fosfodiesteras-inhibitordepressant.
GB8618931D0 (en) 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
US5057517A (en) 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
US5091431A (en) 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
EP0363320A3 (de) 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US4971972A (en) 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
DE69033614T2 (de) 1989-10-20 2001-04-19 Kyowa Hakko Kogyo K.K., Tokio/Tokyo Kondensierte Purinderivate
US5117830A (en) 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
AU3592493A (en) 1992-01-13 1993-08-03 Smithkline Beecham Corporation Pyridyl substituted imidazoles
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
ES2102036T3 (es) 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
CZ14795A3 (en) 1992-07-28 1996-07-17 Rhone Poulenc Rorer Ltd Benzene derivative containing phenyl group bound to aryl or heteroaryl fraction through an aliphatic or hetero atom containing group, process of its preparation and pharmaceutical composition containing thereof
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
NZ257955A (en) 1992-12-02 1996-05-28 Pfizer Catechol diethers pharmaceutical compositions
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
TW263495B (da) 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
FI951367A7 (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Also Published As

Publication number Publication date
KR20010033049A (ko) 2001-04-25
AU747366B2 (en) 2002-05-16
EP1044201A4 (en) 2001-10-31
GB0013780D0 (en) 2000-07-26
JP2002508376A (ja) 2002-03-19
DE69816127T2 (de) 2004-04-22
HUP0100417A2 (hu) 2001-12-28
CA2313150A1 (en) 1999-06-17
EP1045850A4 (en) 2001-10-31
GB2346879A (en) 2000-08-23
EP1045849B1 (en) 2003-07-02
HUP0100305A2 (hu) 2002-01-28
KR100349385B1 (ko) 2002-08-24
JP2002508377A (ja) 2002-03-19
WO1999031103A1 (en) 1999-06-24
US6040447A (en) 2000-03-21
WO1999029694A1 (en) 1999-06-17
DE19882892T1 (de) 2001-02-22
US6211367B1 (en) 2001-04-03
US6057445A (en) 2000-05-02
ES2202924T3 (es) 2004-04-01
EP1045849A1 (en) 2000-10-25
JP2002508379A (ja) 2002-03-19
AU1815999A (en) 1999-07-05
HUP0100417A3 (en) 2002-04-29
WO1999031105A1 (en) 1999-06-24
ATE244243T1 (de) 2003-07-15
DE19882893T1 (de) 2001-02-22
EP1045850A1 (en) 2000-10-25
BR9815169A (pt) 2000-10-10
KR20010032979A (ko) 2001-04-25
HUP0301166A2 (en) 2003-08-28
GB2346878B (en) 2002-12-04
AU1722899A (en) 1999-07-05
KR20010032681A (ko) 2001-04-25
GB0013781D0 (en) 2000-07-26
PL341108A1 (en) 2001-03-26
CA2314335A1 (en) 1999-06-24
AU1722999A (en) 1999-07-05
GB2346879B (en) 2002-12-04
JP2002508378A (ja) 2002-03-19
DE69816127D1 (de) 2003-08-07
US6037470A (en) 2000-03-14
NO20002998L (no) 2000-07-19
PT1045849E (pt) 2003-11-28
EP1044201A1 (en) 2000-10-18
AU1723099A (en) 1999-07-05
GB2346878A (en) 2000-08-23
BR9815171A (pt) 2000-10-10
BR9815170A (pt) 2000-10-10
US6228859B1 (en) 2001-05-08
CN1284077A (zh) 2001-02-14
CN1294590A (zh) 2001-05-09
EP1045849A4 (en) 2001-10-31
WO1999031102A1 (en) 1999-06-24
NO20002998D0 (no) 2000-06-09
CN1281458A (zh) 2001-01-24
AU1820899A (en) 1999-06-28
CA2313004A1 (en) 1999-06-24
WO1999031104A1 (en) 1999-06-24
TR200001706T2 (tr) 2000-11-21
JP3504234B2 (ja) 2004-03-08
JP2001525412A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
DK1045849T3 (da) Purinderivater, der har phosphodiesterase IV inhiberingsaktivitet
YU57603A (sh) Inhibitori fosfodiesteraze 4
WO2003097656A3 (en) Novel substituted sulfamate anticonvulsant derivatives
WO2005061458A3 (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2001009090A3 (fr) Derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinoneses, leurs procedes de preparation et leur application a titre de medicaments
EP2289887A3 (en) Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
MA27078A1 (fr) Derives de 2-amino-thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
DE69901627D1 (de) Verfahren zur Herstellug von 3-Amino-pyrrolidinderivaten
Nakamura et al. An alternative synthesis of d-erythro-sphingosine and l-lyxo-phytosphingosine
WO1998051672A3 (en) A method for the preparation of tertiary amines, a compound useful therefor and alpha-2-receptor active tetrahydroisoquinoline derivatives
KR960029312A (ko) N-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
ATE247638T1 (de) Verfahren zur herstellung von n-alkyl-n'- nitroguanidin
MX9803552A (es) Metodos para producir aminofenilsulfonil carbamidas y productos intermediarios para usarse en el procedimiento.
DE69129894D1 (de) Ein Verfahren zur Darstellung eines 3-alkylierten Indols, Intermediate und ein Verfahren zur Darstellung eines Derivats
WO1998034917A3 (en) Synthesis of acyclic nucleoside derivatives
DE50214837D1 (de) Verfahren zur herstellung von beta-alaninamiden
TH33877A (th) กระบวนการเตรียมอนุพันธ์ 3-อะมิโน-2-ไฮดรอกซี-4-ฟีนิลบิวไทโรไนไดร์ล
DE60321577D1 (de) Verfahren zu deren herstellung
CA2307080A1 (en) Process for preparing 8-cyclopentyl-6-ethyl-3-¬substituted|-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
TH53517A (th) กระบวนการสำหรับการเตรียมเฮทเทอร์โรไซเคิลที่เชื่อมติดกับเบนโซ